|
Synonyms: BMS-224818 | LEA29Y | Nulojix®
belatacept is an approved drug (FDA (2011), EMA (2011))
Compound class:
Peptide
Comment: A recombinant protein fusing the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). CTLA-4 is essential for T-cell co-activation.
Belatecept differs from abatacept by only 2 amino acids. 
View more information in the IUPHAR Pharmacology Education Project: belatacept |
For advanced searching click here to open chemical structure editor
Other Similar Sequences  |
|
| rilonacept |
Targetsnull |
| abatacept |
TargetsCD80; CD86 |
| romiplostim |
TargetsThrombopoietin receptor |
| trebananib |
Targetsnull |
| resokine | |
| efgartigimod alfa |
TargetsFc fragment of IgG receptor and transporter |
| luspatercept |
Targetsnull |
| MK-7110 |
Targetssialic acid binding Ig like lectin 10 |
| inbakicept | |
| sotatercept |
Targetsnull |
| efzofitimod | |
